[Prognosis of panmyelopathy: a retrospective study (author's transl)].
45 patients with pancytopenia were admitted and treated at the 1st Department of Medicine, University of Vienna, between 1972 and 1978. Retrospective analysis disclosed a significantly longer survival time in association with a hypercellular bone-marrow smear. These patients showed a higher incidence of remission with cortisone anabolic therapy, but more often developed acute leukaemia as well. The median survival time of patients with pancytopenia and a hypocellular or blank marrow was five months. This group of patients should, therefore, be considered for early bone-marrow transplantation.
D000293:Adolescent; D000328:Adult; D000368:Aged; D045930:Anabolic Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells; D002648:Child; D003348:Cortisone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000188:drug therapy*; D011379:Prognosis; D012189:Retrospective Studies
D045930:Anabolic Agents; D003348:Cortisone
Die Prognose der Panmyelopathie. Eine retrospektive Studie.